A Phase 3 interventional study of Dexamethasone and Placebo in Severe Burns, sponsored by Nantes University Hospital. Recruiting at 10 sites in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-18.
Sponsored by Nantes University Hospital · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Burns with a site in France — 6 open to participants now, 7 under way, 2 of them phase 3. Burns · France.
Among the 32 studies in Burns with a site in France, this one is the 2nd largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2025, is one of 6 in phase 3, and was the 31st registered.
906 studies on the registry are indexed under Burns; 165 are open to participants now.
Browse Burns studies →6 of the 32 studies in Burns with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Centre Hospitalier Régional Metz-Thionville · Sites in France
Ages 18+
CUTISS AG · Sites in France, Belgium, Germany and 6 more countries
Ages 12+
Centre Hospitalier Régional Metz-Thionville · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–80
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 87 Burns studies recruiting now, 38 (44%) set no upper age limit and 38 (44%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 478 is above the median of 40 across 664 interventional studies indexed under Burns.
Median enrollment 27 across the 22 interventional studies, 72 across the 10 observational. Of the 21 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 32 have an industry lead sponsor. The 10 most frequent:
Nantes University Hospital is the lead sponsor of 839 studies on the registry; 189 are open to participants now.
Nantes University Hospital has 2 studies filed under Burns — fewer than ten, so there is no comparison to draw.
4 of the studies in Burns with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06745557Phase 3CUTISS AGPhase III Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents | 2027-06-30 |
| NCT06487910Centre Hospitalier Régional Metz-ThionvilleDifferential Pressure Distribution Orthosis by 3D Printing Process in the Treatment of Post-burn Hypertrophic Scarring | 2027-01-10 |
| NCT04264065Assistance Publique - Hôpitaux de ParisAlbumin and Prognosis of Severely Patients Burns | 2027-01-16 |
| NCT06469970Centre Hospitalier Régional Metz-ThionvilleEvolution of the Initial Distribution Volume of Glucose in the Severe Burned Adults | 2027-03-28 |
Add all 4 to your calendar (.ics) → With an account.
Among the 32 studies in Burns with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Burns affect more than 11 million people worldwide each year. These injuries are responsible for severe morbidity resulting in a high societal burden and account for more than 180,000 yearly deaths especially in low- and middle-income countries.
Major burns induce an important local and systemic inflammatory response that may be overwhelmed. This inflammation is a physiological phenomenon that favours the healing of tissues. However, the overproduction of inflammatory mediators might lead to an exacerbated Systemic Inflammatory Response Syndrome (SIRS). Recently the total body surface area (TBSA) burned has shown to be well correlated to persistent elevation of pro-inflammatory mediators (such as IL-6). This SIRS, in turn, contributes to the enhanced risk of sepsis, acute respiratory distress syndromes (ARDS) and organ failures in general such as acute kidney injuries (AKI), most of those occurring within the first week of admission.
Corticosteroids (CS) have already proven their effectiveness against SIRS-induced organ dysfunction or mortality in acute medicine notably in septic shock, polytraumatized patients and more recently in the treatment of viral or non-viral ARDS without increasing the risk of secondary bacterial complications or significant side effects . Indeed the recent SCCM Guidelines clearly advocate for the use of CS in severe community-acquired pneumonia, septic shock and ARDS. The investigators recently performed a large multicenter, double-blinded randomized controlled trial (the PACMAN trial, PHRC-N 2016) including 1222 patients scheduled for major surgery in which the investigators observed a major decrease in CRP blood concentrations in the dexamethasone arm. The rate of AKI and the need for mechanical ventilation were also significantly reduced in the intervention arm. ICU Patients with severe burns undergo several surgeries, including major procedures (excision, skin grafts), rendering them quite similar to those in the PACMAN trial in terms of inflammatory response. Very few side effects (hyperglycemia mainly) easily overcome in ICU are usually reported with the use of low-to-moderate dose of CS.
In severe burn patients, very few data are available to date, two retrospective case control studies and a small prospective randomized trial showed promising results when using CS but high quality evidence is lacking.
The investigators hypothesise here that the use of dexamethasone after major burns, the prototypic model of inflammatory response in surgical ICU patients, would limit SIRS-induced organ failure and/or all-cause mortality.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Imminent death and a do-not-resuscitate order
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dexamethasone 0.2 mg/kg of ideal body weight (IBW) IV (at a maximum of 20 mg per day) will be blindly infused from day 1 to day 5
Drug: Dexamethasone
Placebo: one IV administration per day from day 1 to day 5.
Drug: Placebo
Dexamethasone 0.2 mg/kg of ideal body weight (IBW) IV (at a maximum of 20 mg per day) will be blindly infused from day 1 to day 5;
Placebo: one IV administration per day from day 1 to day 5.
Major complications
It's a hierarchic procedure. Major complications defined as moderate to severe ARDS (using Berlin definition criteria) or AKI KDIGO 2 to 3 within 28 days
Time frame: 28 days
All-cause mortality at day 90
Time frame: 90 days
Hospital-acquired infections
Hospital-acquired pneumonia (using the joint definition from the Infectious Diseases Society of America and American Thoracic Society) within 28 days
Time frame: 28 days
Hospital-acquired infections
Catheter-related bloodstream infections within 28 daysDiseases Society of America and American Thoracic Society) within 28 days
Time frame: 28 days
Hospital-acquired infections
other infections, including skin infections (diagnosis confirmed by an independent adjudication committee) with or without bacteraemia within 28 days
Time frame: 28 days
Hospital-acquired infections
Antibiotic-free days on day 28
Time frame: 28 days
Respiratory complications
ARDS (using Berlin Criteria definition) on day 28
Time frame: 28 days
Respiratory complications
Invasive ventilator-free days on day 28
Time frame: 28 days
ICU Length-of-Stay
ICU Length-of-Stay
Time frame: 28 days
Hospital Length-of-Stay
Hospital Length-of-Stay
Time frame: 28 days
risks of organ dysfunction
SOFA scores
Time frame: 14 days
risks of organ dysfunction
KDIGO stages 2 and 3 AKI
Time frame: 28 days
General tolerance of the treatment
Number of Participants with Hyperglycemia
Time frame: 28 days
specific tolerance of the treatment on skin lesions
surgical site infections confirmed by an independent adjudication committee,
Time frame: 28 days
Timing of first surgery
Timing of first surgery on the main endpoint
Time frame: 28 days
Impact of treatment on serum CRP Levels
Serum CRP levels on day 0, day 1, day 3, day 7 and day 14
Time frame: 14 days
General tolerance of the treatment
Number of Participants with hypernatremia
Time frame: 28 days
General tolerance of the treatment
Number of Participants with hypokalaemia
Time frame: 28 days
General tolerance of the treatment
Number of Participants with gastrointestinal bleeding
Time frame: 28 days
General tolerance of the treatment
Number of Participants with acquired-weakness
Time frame: 28 days
Plan to share: No
Started Nov 2025 (actual). Primary completion is estimated for Feb 2029, 39 months after the start.
Of 21 phase 3 interventional studies under Burns, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 59. This study's planned 39 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone